Javascript must be enabled to continue!
Evidence for both in vivo and in vitro interaction between vigabatrin and alanine transaminase
View through CrossRef
Aims Decreases in plasma alanine transaminase (ALA‐T) activity of 20–100% have been reported following the use of vigabatrin (Sabril) in patients with uncontrolled epilepsy. This effect has a potential clinical significance as it may mask signs of early, underlying hepatic disease. It is particularly significant in a patient population known to have a higher than average risk of hepatotoxicity due to treatment with other anti‐epilepsy drugs or to an independent, but concomitant, disease process. Vigabatrin is a highly specific enzyme antagonist. There is an almost 1000‐fold difference between its activity against γ‐amino butyric acid aminotransaminase and ALA‐T. However, some activity against other transaminases is not unexpected, and it is important to determine the degree of vigabatrin's effect against ALA‐T in man. Methods Two in vitro experiments, using serum samples spiked with vigabatrin, confirmed the presence of an interaction between vigabatrin and ALA‐T, and formed the basis for the design of a study in five healthy male volunteers, in whom serum ALA‐T activity was measured before and after a single dose of 1.5 g of vigabatrin. Results Serial sampling confirmed the presence of an in vivo interaction between vigabatrin and ALA‐T, causing an inhibition of enzyme activity of 30–40%. A further 20% reduction was found in vitro in samples taken at the time of the peak plasma vigabatrin concentration after they had been stored for 6 h. Conclusions The clinical significance of these findings is that the levels of ALA‐T activity determined in patients receiving vigabatrin may be inaccurate. The ‘real’ values must be assumed to be higher than those reported after routine testing. To obtain the most realistic measurement of ALA‐T activity in patients, samples should be taken at the times of trough plasma concentration and processed as soon as possible afterwards. Samples stored for any length of time at or above room temperature may also give even more false results.
Title: Evidence for both in vivo and in vitro interaction between vigabatrin and alanine transaminase
Description:
Aims Decreases in plasma alanine transaminase (ALA‐T) activity of 20–100% have been reported following the use of vigabatrin (Sabril) in patients with uncontrolled epilepsy.
This effect has a potential clinical significance as it may mask signs of early, underlying hepatic disease.
It is particularly significant in a patient population known to have a higher than average risk of hepatotoxicity due to treatment with other anti‐epilepsy drugs or to an independent, but concomitant, disease process.
Vigabatrin is a highly specific enzyme antagonist.
There is an almost 1000‐fold difference between its activity against γ‐amino butyric acid aminotransaminase and ALA‐T.
However, some activity against other transaminases is not unexpected, and it is important to determine the degree of vigabatrin's effect against ALA‐T in man.
Methods Two in vitro experiments, using serum samples spiked with vigabatrin, confirmed the presence of an interaction between vigabatrin and ALA‐T, and formed the basis for the design of a study in five healthy male volunteers, in whom serum ALA‐T activity was measured before and after a single dose of 1.
5 g of vigabatrin.
Results Serial sampling confirmed the presence of an in vivo interaction between vigabatrin and ALA‐T, causing an inhibition of enzyme activity of 30–40%.
A further 20% reduction was found in vitro in samples taken at the time of the peak plasma vigabatrin concentration after they had been stored for 6 h.
Conclusions The clinical significance of these findings is that the levels of ALA‐T activity determined in patients receiving vigabatrin may be inaccurate.
The ‘real’ values must be assumed to be higher than those reported after routine testing.
To obtain the most realistic measurement of ALA‐T activity in patients, samples should be taken at the times of trough plasma concentration and processed as soon as possible afterwards.
Samples stored for any length of time at or above room temperature may also give even more false results.
Related Results
Infantile Spasms and Epilepsy Currents
Infantile Spasms and Epilepsy Currents
The United Kingdom Infantile Spasms Study Comparing Vigabatrin with Prednisolone or Tetracosactide at 14 Days: A Multicentre, Randomised Controlled Trial Lux AL, Edwards SW, Hanco...
Control of alanine metabolism in rat liver by transport processes or cellular metabolism
Control of alanine metabolism in rat liver by transport processes or cellular metabolism
1. Factors governing hepatic utilization of alanine were studied in vivo and in vitro in rats adapted to increasing dietary protein. 2. Hepatic alanine utilization was enhanced 5-f...
Vigabatrin versus ACTH in the treatment of infantile spasms
Vigabatrin versus ACTH in the treatment of infantile spasms
OBJECTIVE: To compare adrenocorticotropic hormone with vigabatrin as a single mono-therapy for infantile spasms. We studied hospitalization time, clinical response, whether complet...
Clinical pharmacology of vigabatrin.
Clinical pharmacology of vigabatrin.
1. Upon oral administration vigabatrin is rapidly absorbed. Plasma elimination half‐life ranges between 5 and 7 h in normal volunteers. Vigabatrin is eliminated primarily via the k...
Investigation of alanine dosimeter for output measurement in radiotherapy: Results from multicenter in Thailand
Investigation of alanine dosimeter for output measurement in radiotherapy: Results from multicenter in Thailand
Background: Alanine dosimeters are generally used in high-dose industrial applications (kGy). Later, research into employing alanine as a dosimeter in radiotherapy (1-20 Gy) has in...
Involvement of capsaicin-sensitive primary afferent fibers in regulation of jejunal alanine absorption
Involvement of capsaicin-sensitive primary afferent fibers in regulation of jejunal alanine absorption
Capsaicin-sensitive primary afferent fibers (CSPA) in the small intestine regulate many functions through the release of peptides and neurotransmitters. This study was undertaken t...
121 DIFFERENTIAL mRNA EXPRESSION BETWEEN IN VIVO AND IN VITRO-DERIVED BOS INDICUS AND BOS TAURUS EMBRYOS
121 DIFFERENTIAL mRNA EXPRESSION BETWEEN IN VIVO AND IN VITRO-DERIVED BOS INDICUS AND BOS TAURUS EMBRYOS
Brazil is a leading country in the world of commercial use of in vitro-produced bovine embryos with 200 000 transfers per year. The majority of in vitro-produced embryos are pure b...
A concise review on analytical profile of Vigabatrin
A concise review on analytical profile of Vigabatrin
Vigabatrin (VGB) is a drug of Anticonvulsant class. It works by decreasing abnormal electrical activity in the brain. It inhibits the GABA-degrading enzyme i.e. GABA transaminase, ...

